What Is MCAD Deficiency? Causes, Symptoms, and Treatment

MCAD deficiency (medium-chain acyl-CoA dehydrogenase deficiency) is an inherited condition in which the body cannot properly break down certain fats for energy. It is one of the most common inborn errors of metabolism, affecting roughly 1 in 15,000 newborns worldwide, and it becomes dangerous when a child or adult goes too long without eating or faces illness-related stress on the body.¹ The good news is that early detection through newborn screening and straightforward dietary precautions allow most people with the condition to live healthy, largely normal lives.

How the Body Uses Fat and Where Things Go Wrong

Your body stores energy in fat, and when you go without food for a stretch, your cells begin breaking down that stored fat to keep running. This process happens inside mitochondria, the energy-producing compartments within each cell. MCAD is one of several enzymes responsible for a specific step in that breakdown, handling medium-length fat molecules. When the enzyme is absent or barely functional, those medium-chain fats stall out instead of being converted into usable fuel.

The immediate problem is an energy gap. During fasting or illness, your body expects to switch from burning sugar to burning fat. With MCAD deficiency, that switch fails. Blood sugar can plummet because the body has already used up its sugar stores and cannot tap into fat reserves to compensate. At the same time, partially processed fat molecules build up and can become toxic to cells. Research on cells from people with the condition has shown that the damage goes beyond just the fat-burning pathway: mitochondrial function overall is disrupted, with measurable drops in the activity of other energy-producing components inside the cell.²

The Genetic Cause

MCAD deficiency is caused by mutations in a single gene called ACADM, which provides the blueprint for the MCAD enzyme. It follows an autosomal recessive pattern, meaning a child must inherit a faulty copy of the gene from each parent to develop the condition. Parents who each carry one working copy and one faulty copy are called carriers; they produce enough enzyme themselves and typically have no symptoms.

One particular mutation dominates. A single letter change in the DNA, known as c.985A>G, accounts for the vast majority of cases in people of European descent. About 81% of affected individuals carry two copies of this mutation, and another 18% carry one copy of it alongside a different, rarer mutation.¹ In a worldwide compilation of data from 172 unrelated families, the same mutation appeared in 90% of all disease-causing gene copies identified.³ The condition is especially common in populations with northwestern European ancestry, though newborn screening programs have revealed cases across ethnic groups.

England’s screening program offers a useful snapshot. Among about 1.5 million screened babies, the prevalence of confirmed MCAD deficiency was roughly 1 in 10,600. About 70% of confirmed cases carried gene variants of definite clinical importance, while 30% had variants whose long-term significance remains uncertain.⁴ That second group is important: some mutations leave the enzyme partially functional rather than completely absent, and these milder forms may never cause a crisis. The challenge for doctors and families is that “milder on paper” does not always mean “no risk in practice.”

Symptoms and What Triggers a Crisis

Between episodes, most people with MCAD deficiency look and feel completely well. The condition typically reveals itself during the first two years of life when a young child faces a combination of fasting and metabolic stress, such as a stomach bug that causes vomiting, a fever from a common cold, or simply sleeping through the night for the first time without a feed.⁵ Undiagnosed individuals are generally asymptomatic until one of these episodes of increased energy demand and fasting occurs.⁶

The hallmark of a crisis is dangerously low blood sugar without the expected rise in ketones, the backup fuel molecules the body usually produces from fat. Doctors call this “hypoketotic hypoglycemia.” Symptoms escalate quickly:

Early signs: lethargy, poor feeding, irritability, and vomiting
Progressing: confusion, unresponsiveness, and seizures as the brain runs out of fuel
Severe: coma and, if untreated, death from complete metabolic collapse

Before widespread newborn screening, many children with MCAD deficiency were only diagnosed after their first serious crisis, and some were not diagnosed at all. Tragically, some cases were mistaken for sudden infant death or Reye syndrome, a condition that also involves liver swelling and brain dysfunction. Detailed examination of liver tissue can distinguish the two, because MCAD deficiency leaves a distinct pattern of fat accumulation and mitochondrial abnormalities not seen in Reye syndrome.⁷

How It Is Diagnosed

Today, most cases are caught before any symptoms appear, thanks to newborn screening. Within the first few days of life, a small blood sample is taken from a baby’s heel and analyzed. The test uses a technology called tandem mass spectrometry to measure the levels of specific fat-breakdown byproducts called acylcarnitines in the blood. Babies with MCAD deficiency show a characteristic spike in medium-chain acylcarnitines, especially one called octanoylcarnitine (C8).⁸ Many screening programs now also monitor the ratio between different acylcarnitines to improve accuracy and reduce false positives.⁹

A positive screening result does not automatically mean a child has the condition. In England’s large screening program, the positive predictive value was 77%, meaning that about three out of four babies flagged by the screen truly had MCAD deficiency; the rest were false positives.⁴ Confirmation requires genetic testing for mutations in the ACADM gene and sometimes additional biochemical tests. When MCAD deficiency is suspected after symptoms have already appeared, the same acylcarnitine profile is measured, along with blood sugar, ketone levels, and liver function tests.

There are also other fatty acid oxidation disorders that can look similar. Specialized testing can distinguish MCAD deficiency from conditions like VLCAD deficiency or LCHAD deficiency by identifying the specific pattern of acylcarnitine species that accumulate. Each disorder leaves a different biochemical fingerprint.¹⁰

Treatment and Day-to-Day Management

There is no cure for MCAD deficiency and no way to replace the missing enzyme. Treatment centers entirely on prevention: avoiding the situations that trigger a metabolic crisis. In practice, this means three things: don’t fast too long, respond quickly to illness, and keep carbohydrate-rich fuel available.

Fasting guidelines are age-dependent. A widely used set of recommendations advises that infants between six months and one year should not go longer than 8 hours without food, children in their second year can stretch to 10 hours, and from age two onward, 12 hours is considered the safe upper limit under normal circumstances.¹¹ During illness, especially with fever, vomiting, or diarrhea, those windows shrink considerably because the body burns through energy stores faster. The same guidelines emphasize redistributing normal daily calories across more frequent meals rather than simply adding extra food on top of what the child already eats, to avoid excessive weight gain.

When a child with MCAD deficiency becomes ill and cannot keep food down, the situation can become an emergency. Parents are typically given an “emergency protocol” that involves offering frequent drinks of a sugar-rich solution, such as glucose polymer drinks. If oral intake is not possible because of vomiting, the child needs to go to the hospital for intravenous glucose. Speed matters: a metabolic crisis can develop within hours. Most metabolic centers issue families with an emergency letter explaining the condition and the need for prompt glucose treatment, so that emergency room staff who may not be familiar with the disorder can act quickly.

The L-Carnitine Debate

Carnitine is a natural molecule that helps shuttle fats into mitochondria for burning. People with MCAD deficiency often have lower-than-normal blood carnitine levels, because carnitine gets “used up” binding to the medium-chain fat fragments that accumulate. This led to the idea that supplementing with L-carnitine might help by mopping up those toxic byproducts.

The evidence, though, is mixed. A pilot study of four young patients found biologically meaningful improvements in exercise capacity after just four weeks of supplementation, with gains of 18 to 32% in peak oxygen uptake.¹² Another study, however, found that while L-carnitine supplementation increased the clearance of accumulated acylcarnitines during moderate exercise, it produced no apparent clinical or biochemical benefit. Patients in that study completed two hours of moderate-intensity exercise after a 12-hour fast without any adverse effects, even without supplementation.¹³ In adults with the condition, L-carnitine supplementation did not improve the rate at which the body burned fat during exercise.¹⁴

The result is that routine carnitine supplementation remains controversial. Some metabolic centers prescribe it as a precaution, especially for young children; others reserve it for patients who show measurably low carnitine levels. Neither approach is clearly right or wrong with current evidence, and most guidelines leave it to the treating physician’s judgment.

Exercise and Physical Activity

Parents often worry about whether their child with MCAD deficiency can safely play sports or be physically active. The short answer is yes, with reasonable precautions. The body’s reliance on fat as a fuel source increases during prolonged exercise, which is where the risk lies. Studies show that adults with the condition burn fat at roughly half the rate of healthy individuals during sustained cycling, confirming that the metabolic limitation is real and persists into adulthood.¹⁴ But the patients in these studies completed strenuous exercise protocols without clinical problems, as long as they were well-fed beforehand.

The practical takeaway: eat a carbohydrate-rich snack before and during prolonged activity, avoid exercising on an empty stomach, and stay alert for signs of low blood sugar like shakiness, confusion, or unusual fatigue. High-intensity activities of short duration, like a sprint or a set of jumps, rely mainly on sugar rather than fat and pose less theoretical risk. Endurance activities, like long-distance running or all-day hiking, require more careful fueling.

Long-Term Outlook and Neuropsychological Effects

For children identified through newborn screening and managed with appropriate fasting precautions, the prognosis is generally excellent. A study comparing screened and unscreened children with MCAD deficiency found no evidence of overall intellectual impairment in either group. However, children diagnosed only after a symptomatic crisis showed some signs of weaker verbal ability and specific aspects of planning skills, suggesting that severe episodes of low blood sugar can leave subtle marks on brain development.¹⁵ Children diagnosed early and those who had more contact with the healthcare system (measured by hospitalizations) actually scored higher on verbal, communication, and socialization measures, possibly because closer medical follow-up and parent education translated into more attentive developmental support.

The risk of crisis does not disappear with age. Adults with MCAD deficiency still cannot burn medium-chain fats properly, and extreme fasting, heavy alcohol use, or serious illness can provoke a crisis at any age. Awareness tends to become the biggest challenge: adults who have never had a symptomatic episode may underestimate the risk or lose touch with metabolic specialists.

The Value of Newborn Screening

MCAD deficiency is sometimes described as the poster child for expanded newborn screening. The condition is common enough to justify testing, a simple and inexpensive blood test reliably detects it, and the available treatment, while not a cure, prevents nearly all serious harm. An economic model from Washington State projected a benefit-to-cost ratio of 3.4 to 1 for MCAD screening, based on expected reductions in infant mortality and serious developmental disability.¹⁶ Despite this, screening practices have historically varied between states and countries, with some adopting MCAD testing early and others lagging behind.¹⁷ Today, MCAD deficiency is included in the recommended uniform screening panel in the United States and is screened for in most of Europe and Australia.

The Connection to Pregnancy Complications

An unexpected twist in the MCAD deficiency story involves pregnancy. A condition called acute fatty liver of pregnancy (AFLP), a rare and potentially life-threatening liver disorder that strikes in the third trimester, has been linked to carrying a fetus with a defect in fatty acid oxidation. The theory is that the fetus’s inability to process certain fats leads to a buildup of toxic metabolites that cross the placenta and damage the mother’s liver. This association means that a mother who develops AFLP may benefit from having her newborn screened for fatty acid oxidation disorders, including MCAD deficiency, even beyond routine newborn screening protocols. The connection also has implications for future pregnancies and genetic counseling.¹⁸

Life With MCAD Deficiency as a Family

The medical picture of MCAD deficiency is straightforward compared to many genetic conditions, but the day-to-day reality for families can be more draining than outsiders might expect. The biggest burden, especially in infancy, is the constant vigilance around feeding schedules. Parents of young children with MCAD deficiency describe fixed feeding schedules with short fasting windows, feeding by the clock regardless of whether the child seems hungry, and chronic sleep deprivation from nighttime feeds.¹⁹ Research on families managing inherited metabolic diseases found that maintaining a safe fasting interval was the single greatest restriction on family life during infancy, and that dietary interventions placed a higher burden on family life in the first four years than later on.²⁰

The emotional toll extends beyond feeding logistics. In a cross-sectional study of caregivers for children with inherited metabolic diseases, 82% reported mental struggles related to caregiving, and nearly half spent four or more extra hours per week on care-related tasks at home.²¹ Sleep disruption is a recurring theme, with over half of mothers and nearly half of fathers in one study reporting significant sleep problems from interrupted nights.¹⁹ Fear of metabolic crises hangs over everyday decisions, from daycare drop-off to family vacations. Every childhood stomach bug becomes a potential emergency.

The encouraging pattern, though, is that the burden lightens as children grow. Older children tolerate longer overnight fasts, understand their own need to eat regularly, and face fewer illnesses that require emergency-level intervention. By school age, many families describe the condition as something they manage in the background rather than something that dominates their lives. Connecting with other affected families through patient organizations and metabolic disease networks is something many parents cite as genuinely helpful for navigating the early, more anxious years.